KSKazim Secgen

Kazim Secgen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kazim Secgen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • A Homozygous ALCAM–CBLB Deletion at 3q13.11‐q13.12 Defines a Candidate Novel Oculo‐Skeletal‐Immune Contiguous Gene Deletion Syndrome

    by Nilay Kan Menkü, Mehlika Meryem Sarı, Filiz Başak Ergin, Tuğçe İnal, Kazım Seçgen, Avniye Kübra Baskın, Rüştü Fikret Akata, Fatih Ezgü

    To our knowledge, we report the first combined homozygous deletion of ALCAM and CBLB at 3q13.11‐q13.12. The patient, a 14‐year‐old boy born to consanguineous parents, had a multisystem phenotype with severe congenital ocular and craniofacial anomalies, early‐onset osteoporosis, progressive scoliosis, growth failure, congenital heart defect, humoral immunodeficiency, and chronic inflammatory findings. SNP array identified a 2.5‐Mb homozygous deletion spanning ALCAM and CBLB , and expression studies confirmed complete absence of ALCAM and CBLB expression. Whole‐exome sequencing did not identify an alternative molecular diagnosis. The clinical presentation is likely attributable to combined ALCAM and CBLB loss. Previous animal‐model studies support interpretation of the individual phenotypic components by linking loss of these genes to craniofacial developmental abnormalities, skeletal findings, and immune dysregulation. We propose that this deletion may represent a candidate novel contiguous gene deletion syndrome. This case is the first human phenotype associated with complete ALCAM loss in a contiguous deletion and expands the clinical spectrum associated with disruption of ALCAM and CBLB .

  • Open Access

    The Role of Genetics in Congenital Heart Disease-Associated Pulmonary Arterial Hypertension

    by Fatma Hayvaci Canbeyli, Kazim Secgen, Fatih Suheyl Ezgu, Gulten Tacoy, Serkan Unlu, Hidayet Ozan Arabacı, Ayhan Pektas, Aslı Inci, Ergun Barıs Kaya, Umit Yasar Sinan, et al.

    Pulmonary arterial hypertension associated with congenital heart disease (APAH-CHD) is a severely progressive condition with complex pathogenesis. The aim of this study was to evaluate the contribution of genetic variants to the development of PAH in patients with APAH-CHD. Fifteen children and twenty-seven adults diagnosed with APAH-CHD were enrolled. Targeted next-generation sequencing was performed on PAH-associated genes ( ABCC8 , ACVRL1 , AQP1 , ATP13A3 , BMPR2 , CAV1 , GDF2 , GGCX , EIF2AK4 , ENG , KCNK3 , KDR , KLK1 , SMAD1 , SMAD4 , SMAD9 , SOX17 , TBX4 , TET2 ). A total of 21 distinct variants across 11 different genes were detected in 17 of the 42 patients. ( ABCC8 = 2, ACVRL1 = 1, ATP13A3 = 2, BMPR2 = 4, GGCX = 1, EIF2AK4 = 2, ENG = 1, KDR = 3, SMAD1 = 1, SMAD9 = 1, TET2 = 3). Five of the patients with the mutation were under the age of 18, and 12 patients were adults. The most common CHD in patients with detected variants was VSD. PAH-related genetic variants were not uncommon in APAH-CHD patients. Our study identified 12 novel variants that may help to understand the genetic basis of APAH-CHD. Trial Registration The study has been registered on ClinicalTrials.gov with the identification number NCT05550389.